Korean Journal of Head & Neck Oncology (대한두경부종양학회지)

The Korean Society for Head and Neck Oncology (대한두경부종양학회)
권호 표지

Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma

비인강암의 동시 항암화학방사선치료

  • Chung, Eun-Ji (Departments of Radiation Oncology, National Health Insurance Corporation Ilsan Hospital) ;
  • Kim, Yong-Tai (Departments of Internal Medicine, National Health Insurance Corporation Ilsan Hospital) ;
  • Hong, Hyun-Jun (Departments of Otolaryngology, National Health Insurance Corporation Ilsan Hospital) ;
  • Hong, Won-Pyo (Departments of Otolaryngology, National Health Insurance Corporation Ilsan Hospital)
  • 정은지 (국민건강보험공단 일산병원 방사선종양학과) ;
  • 김용태 (국민건강보험공단 일산병원 혈액종양내과) ;
  • 홍현준 (국민건강보험공단 일산병원 이비인후과) ;
  • 홍원표 (국민건강보험공단 일산병원 이비인후과)
  • Published : 2008.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose：This is a retrospective study to evaluate the results of concurrent chemoradiotherapy in nasopharyngeal carcinoma. Material and Methods：From Mar 2000 to June 2005, 18 patients with nasopharyngeal carcinoma completed planned concurrent chemoradiotherapy. Stages were I in 1 patients, II in 2 patients, III in 7 patients and IV in 8 patients. Pathologic type was squamous cell carcinoma(WHO type 1) in 2 patients, non-keratinizing type(WHO type 2) in 8 patients and undifferetiated carcinoma(WHO type 3) in 8 patients. The follow up period ranged from 30 months to 95 months with a median of 56 months. Follow up was possible in all patients. Results：Response to concurrent chemoradiation therapy was a complete response in all patients. Patterns of failure were as follows：local recurrence in only one patient(5.6%) and distant metastases in three patients with N3 diseases(16.7%). The overall 5 year survival rates were 88.5%, the 5 year disease free survival rate was 77% and these were very good results. There were no significant differences in the local control and survival rates between the clinical stages and pathologic types. Conclusion：The outcome of the nasopharyngeal carcinoma treated with concurrent chemoradiotherapy was very good, even though most of the patients(15/18=83.3%) were in stage III and IV diseases. We concluded that concurrrent chemoradiotherapy in nasopharyngeal carcinoma showed the good local control and survival rates without significant complications. In the patients with N3 disease, we have to consider the more effective and strong chemotherapeutic regimens to prevent distant metastases.

Keywords

References

  1. Geara FB, Sanguineti G, Tucker SL, Garden AS, Ang KK, Morrison WH, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: Determinants of distant metastasis and survival. Radiother Oncol. 1997;43:53-61 https://doi.org/10.1016/S0167-8140(97)01914-2
  2. Su CK, Wang CC. Prognostic value of Chinese race in nasopharyngeal cancer. Int J Radiat Oncol Biol Phys. 2002;54:725-758 https://doi.org/10.1016/S0360-3016(02)02969-3
  3. Teo P, Yu P, Lee WY, Leung SF, Kwan WH, Yu KH, et al. Significant prognostic factors after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Radiat Oncol Biol Phys. 1996;36:291-304
  4. Shin YS, Kim JH, Kim KR. Clinical study of malignant tumors of the nasopharynx. Korean J Otolaryngol. 1989;32:879-887
  5. Liu MT, Hsieh CY, Chang TH, Lin JP, Huang CC, Wang AY. Prognostic factors affecting the outcome of nasopharyngeal carcinoma. Jpn J Clin Oncol. 2003;33:501-508 https://doi.org/10.1093/jjco/hyg092
  6. Farias TP, Dias FL, Lima RA, Kligerman J, de Sa GM, Barbosa MM, et al. Prognostic factors and outcome for nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:794-799 https://doi.org/10.1001/archotol.129.7.794
  7. Sanguineti G, Geara FB, Garden AS, Tucker SL, Ang KK, Morrison WH, et al. Carcinoma of nasopharynx treated by radiotherapy alone: Determinants of local and regional control. Int J Radiat Oncol Bio Phys. 1997;37:985-996 https://doi.org/10.1016/S0360-3016(97)00104-1
  8. Bailet JW, Mark RJ, Abemayor E, Lee SP, Tran LM, Juillard G, et al. Nasopharyngeal carcinoma: treatment results with primary radiation therapy. Laryngoscope. 1992;102:965-972
  9. Kim TH, Ko YH, Lee MA, Kim BS, Chung SR, Yoo IR, et al. Treatment outcome of cisplatin based chemoradiotherapy in patients with locally advanced nasopharyngeal cancer. Cancer Res Treat. 2008;40:52-70
  10. Fuchs S, Rodel C, Brunner T, Iro H, Niedobitek G, Sauer R, et al. Patterns of failure following radiation with and without chemotherapy in patients with nasopharyngeal carcinoma. Onkologie. 2003;26:12-18 https://doi.org/10.1159/000069858
  11. Tombolini V, De Sanctis V, Donato V, Osti MF, Raffetto N, Santarelli M, et al. Prognostic features and treatment outcome in patients with nasopharyngeal carcinoma: An experience of 20 years. Anticancer Res. 2001;21:1413-1418
  12. Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005;23:6966-6975 https://doi.org/10.1200/JCO.2004.00.7542
  13. Zhang L, Zhao C, Peng PJ, Lu LX, Huang PY, Han F, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: Preliminary results. J Clin Oncol. 2005;23: 8461-8468 https://doi.org/10.1200/JCO.2004.00.3863
  14. Erkal HS, Serin M, Cakmak A. Nasopharyngeal carcinomas: Analysis of patient, tumor and treatment characteristics determining outcome. Radiother Oncol. 2001;61:247-256 https://doi.org/10.1016/S0167-8140(01)00448-0
  15. Chung WK, Cho JS, Park SJ, Lee JH, Ahn SJ, Nam TK, et al. An analysis on factors affecting local control and survival in nasopharyngeal carcinoma. J of Korean Soc Ther Radiol Oncol. 1999; 17:91-99
  16. Lee AW, Poon YF, Foo W, Law SC, Cheung FK, Chan DK, et al. Retrospective analysis of 5,307 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;23:261-270 https://doi.org/10.1016/0360-3016(92)90740-9
  17. Perez CA, Devineni VR, Marcial-Vega V, Marks JE, Simpson JR, Kucik N. Carcinoma of the nasopharynx: Factors affecting prognosis. Int J Radiat Oncol Biol Phys. 1992;23:271-280 https://doi.org/10.1016/0360-3016(92)90741-Y
  18. Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa P, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: An update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53:12-22 https://doi.org/10.1016/S0360-3016(02)02724-4
  19. Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: Positive effect on overall and progression-free survival. J Clin Oncol. 2003;21:631-637 https://doi.org/10.1200/JCO.2003.06.158
  20. Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, et al. Nasopharyngeal carcinomas: an update. Eur J Cancer. 2003; 39:2121-2135 https://doi.org/10.1016/S0959-8049(03)00367-8